Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, outlines current investigational approaches targeting BCMA in multiple myeloma. These include belamatamab mafoditin, an antibody-drug conjugate evaluated in the DREAMM-2 study (NCT03525678) as well as CAR T-cell therapies investigated in CARTITUDE-1 (NCT03548207) and KarMMA (NCT03361748). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).